APDA Information and Referral center09/01/1998 - 08/31/2024 (PI)
American Parkinson Disease Association, Inc.
APDA Advanced Center for Parkinson's Research09/01/1998 - 08/31/2023 (PI)
American Parkinson Disease Association, Inc.
American Parkinson Disease Association Administrative Support Grant09/01/2017 - 08/31/2021 (PI)
American Parkinson Disease Association, Inc.
American Parkinson Disease Association Information and Referral Center09/01/2019 - 08/31/2020 (PI)
American Parkinson Disease Association, Inc.
American Parkinson Disease Association Administrative Support Grant09/01/2018 - 08/31/2019 (PI)
American Parkinson Disease Association, Inc.
A Randomized, Double Blind, Placebo Controlled Study of SD-809 Extended Release for the Treatment of Chorea associated with Huntington Disease10/01/2013 - 01/31/2018 (PI)
Auspex Pharmaceuticals, Inc.
American Parkinson Disease Association (APDA) Staff Grant02/01/2016 - 08/31/2016 (PI)
American Parkinson Disease Association, Inc.
Sphermine07/01/2003 - 10/31/2015 (PI)
Berlex
APDA Information and Referral center09/01/2014 - 08/31/2015 (PI)
American Parkinson Disease Association, Inc.
Center for Advanced Research in Parkinson's Disease09/01/2014 - 08/31/2015 (PI)
American Parkinson Disease Association, Inc.
Showing 10 of 43 results.
Show All Results
A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To determine the Safety, Tolerability and Efficacy of Three Doses of Once Daily P2B00102/21/2014 - 02/20/2015 (PI)
Pharma Two B Ltd.
APDA Center for Advanced Research in Parkinson's Research09/01/2013 - 08/31/2014 (PI)
American Parkinson Disease Association, Inc.
Information and Referral Center09/01/2013 - 08/31/2014 (PI)
American Parkinson Disease Association, Inc.
A phase 2b, randomized, double-blind placebo-controlled study investigating the efficacy and safety of inhaled CVT-301 (Levodopa Inhalation Powder) in Parkinson's disease patients with motor response04/01/2013 - 12/31/2013 (PI)
Civitas Therapeutics, Inc.
Phase 2 Randomized Double-Blind, Placebo-Controlled Parallel Group Multicenter Study to Evaluate the Safety Tolerability and Efficacy of ADX48621 in the Treatment of Levodopa Induced Dyskinesia in Pat10/01/2011 - 09/30/2013 (PI)
Addex Pharmaceuticals
A phase III, double-blind, placebo-controlled randomised trial to determine the efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, as add-on therapy, in subjects w09/01/2010 - 08/31/2011 (PI)
Serono Inc
An open-label, multi-center, follow-up study designed to evaluate the long-term effects of rasagiline in Parkinson's disease subjects who participated in the ADAGIO study07/01/2009 - 06/30/2011 (PI)
Teva Neuroscience, LLC
Prospective Huntington At Risk Observational Study (PHAROS)09/30/2002 - 06/30/2010 (PI)
University of Rochester NIH NHGRI
Advanced Center for Parkinson’s Research09/01/2003 - 08/31/2009 (PI)
American Parkinson Disease Association, Inc.
APDA Information and Referral Center09/01/1998 - 08/31/2009 (PI)
American Parkinson Disease Association, Inc.
E2007-G0000-303 A Multi-Center, Open Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of E2007 as an Adjunctive Therapy in Levodopa Treated Parkinson’s Disease Patients with Motor Fluctuations07/18/2006 - 06/30/2009 (PI)
Eisai Medical Research Institute, Inc.
An Open-Label Multicenter Study of the Continued Safety of Istradefylline (KW-6002) in Subjects with Parkinson's Disease Who Have Recently Completed One Year of Treatment with Istradefylline10/01/2005 - 02/28/2009 (PI)
Kyowa Hakko Kirin Pharma, Inc.
A Multicenter, Double-Blind, Randomized Start, Placebo-controlled, Parallel-Group Study to Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease Subjects09/23/2005 - 12/31/2008 (PI)
Teva Neuroscience, LLC
A Long Term, Double-Blind, Randomized, Parallel-Group, Carbidopa/Levodopa Controlled, Multi-Center Study to Evaluate the Effect of Stalevo in Patients with Parkinson’s Disease Requiring Initiation of Levodopa Therapy07/01/2004 - 10/31/2008 (PI)
Novartis Pharmaceuticals Corporation
An Open-label, Multicenter, Multinational Phase III Follow-up Study to Investigate the Long-term Safety and Efficacy of Sarizotan HCI 1mg B.I.D. in Patients with Parkinson’s Disease Suffering from Treatment-associated Dyskinesia (PADDY-O)06/13/2005 - 06/12/2008 (PI)
Merck & Company, Inc.
Gene-Metal Interactions and Parkinson’s Disease04/01/2002 - 03/31/2007 (PI)
Brigham & Women's Hospital NIH NIEHS
A Double-Blind, Placebo-Controlled, Multicenter Multinational Phase III Trial to Evaluate the Safety and Efficacy of Sarizotan HCL 1 mg b.i.d. in Patients with Parkinson’s Disease Suffering from Treatment-Associated Dyskinesias (PADDY 2)09/21/2004 - 01/15/2006 (PI)
Merck KGaA (Germany)
Investigating Effects of Short-Term Treatment with Pramipexole or Levodopa on B-CIT and SPECT Imaging in Early Parkinson’s Disease06/24/2004 - 06/23/2005 (PI)
Institute for Neurodegenerative Disorders
A Phase II Placebo Controlled, Double Blind Trial of ACP-103 in the Treatment of Psychosis in Parkinson’s Disease02/01/2004 - 01/31/2005 (PI)
Acadia Pharmaceuticals
Open-Label, Long Term, Flexible Dose Study of Safety, Tolerability; and Therapeutic Response in Patients with Parkinson’s Disease - PNU 95666E02/27/2001 - 12/31/2004 (PI)
Pharmacia & Upjohn Company
A Long-Term, Multicenter, Open-Label, Safety Study with a Flexible Long-Term Dose Range of KW-6002 as Treatment for Parkinson’s Disease in Patients with Motor Response Complications on Levodopa/Carbidopa Therapy10/15/2002 - 10/15/2004 (PI)
Kyowa Pharmaceutical, Inc.
A 4-Week Multicenter, Open-Label, Single Arm Study Accessing Tolerability of Triple Combination (TC) in Parkinson’s Disease Patients who Experience End of Dose Wearing Off with Levodopa02/01/2003 - 01/31/2004 (PI)
Novartis Pharmaceuticals Corporation
Incidence and Characteristics of Melanoma in PD Patients02/01/2003 - 01/31/2004 (PI)
Teva Neuroscience, LLC
SPIRID02/01/2003 - 01/31/2004 (PI)
Monitoring Force USA
Guilford 0501-0201 Study to Evaluate the Effects of GPI 148510/01/2002 - 09/30/2003 (PI)
Guilford Pharmaceutical, Inc.
SPIRID Study (EMR 62 2225-006)07/01/2002 - 06/30/2003 (PI)
Monitoring Force USA
Pilot Huntington At Risk Observational Study (PHAROS)07/01/1999 - 06/30/2003 (PI)
University of Rochester NIH CC
A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study of the Efficacy of Doses 20 and 60 mg/day KW-6002 as Treatment for Parkinson’s Disease in Patients with Motor Response Complications of Levodopa/Carbidopa Therapy04/01/2002 - 03/31/2003 (PI)
Kyowa Pharmaceutical, Inc.
Double-blind, Placebo-Controlled, Dose-Response Study of Tolerability, Safety, and Efficacy in Patients with Early Parkinson’s Disease07/01/2000 - 12/31/2001 (PI)
Pharmacia & Upjohn Company
A Multicenter, Double Blind, Placebo Controlled Study to Assess the Tolerability and Effect of Entacapone on the Quality of Lifein Parkinson’s Disease Patients Treated with Levodopa/Carbidopa Experiencing End of Dose Wearing Off03/15/2000 - 12/31/2001 (PI)
Novartis Pharmaceuticals Corporation
An Open Label Extension Study of Remacemide Hydrochloride 300 mg bid in Subjects with Huntington’s Disease03/23/2000 - 06/30/2001 (PI)
AstraZeneca
A 12-Week , Double Blind, Placebo-Controlled, Parallel Group, Multicenter, Exploratory Study of the Safety and Efficacy of KW-6002 as Adjunctive Therapy in Patients with Parkinson’s Disease Who Have Motor Response Complications on Levodopa/Carbidopa10/07/1999 - 09/30/2000 (PI)
MEDEX Clinical Trial Services Inc (behalf of Somerset Pharmaceuticals Inc)
Roche Sample Repository Research Project in Association with Patients Formerly Enrolled in Tasmar (Ro 40 7592), #WN1611703/01/2000 - 08/31/2000 (PI)
Roche Global Development
A Prospective Registry Study in a Global Huntington's Disease Cohort (Enroll-HD)02/02/2020 - 02/01/2026 (PI)
CHDI Foundation
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants with Parkinson’s Disease.10/21/2022 - 10/20/2025 (PI)
Biogen, Inc
Trial Of Parkinson's And Zoledronic acid (TOPAZ)04/29/2021 - 04/30/2024 (PI)
Parkinson's Disease Foundation
American Parkinson Disease Association Administrative Assistant Funds09/01/2021 - 08/31/2023 (PI)
American Parkinson's Disease Association
Synuclein-One Study09/30/2020 - 08/31/2023 (PI)
CND Life Sciences National Institutes
A 36-Week, Multicenter, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy04/15/2020 - 04/15/2023 (PI)
Neuraly, Inc.
PPMI 2.007/07/2020 - 06/30/2022 (PI)
Michael J Fox Foundation
228PD20101/09/2018 - 01/09/2022 (PI)
Biogen, Inc
The Parkinson's Progression Markers Initiave (PPMI)01/01/2020 - 12/31/2021 (PI)
Michael J Fox Foundation
P2B0001/00303/27/2018 - 03/27/2021 (PI)
Pharma Two B
Showing 10 of 23 results.
Show All Results
INO-PD-P#-2014 SURE06/07/2016 - 12/31/2020 (PI)
Northwestern University National Institute o1U01NS090259-01A1
IN11004OLE11/17/2017 - 11/17/2020 (PI)
Intec Pharma Ltd.
Phase 3, Randomized, Double Blind, Placebo Controlled Study02/01/2015 - 02/01/2020 (PI)
Civitas Therapeutics, Inc.
Intec Pharma IPH11004-11004X04/05/2017 - 07/01/2019 (PI)
Intec Pharma Ltd.
Protocol CVT-301-00907/26/2016 - 07/01/2019 (PI)
Acorda Therapeutics
12 Month Dose Level Blinded Study Investigating the safety and efficacy of CVT-30102/01/2015 - 07/01/2019 (PI)
Civitas Therapeutics, Inc.
Clinical Coordination Center for STEADY PD-308/01/2014 - 07/01/2019 (PI)
Northwestern University
The Emergence and Evolution of Social self-management of Parkinson's Disease04/01/2013 - 03/31/2018 (PI)
Tufts University NIH-NINR
Eltoprazine in the Treatment of Levodopa Induced Dyskinesia in Patients with Parkinsons's Disease07/21/2015 - 12/31/2016 (PI)
Amarantus Bioscience Holdings, Inc.
Post Cept09/01/2005 - 12/31/2014 (PI)
University of Rochester NIH-NINDS
Inosine for Parkinson's Disease: Safety and Trial Design Optimization02/15/2009 - 10/31/2012 (PI)
Mass General Hosp Michael J. Fox Found
Steady PD05/01/2009 - 07/31/2012 (PI)
Northwestern University Michael J. Fox Found
Prospective Huntington at risk observational study (PHAROS)09/27/2007 - 06/30/2011 (PI)
University of Rochester NIH